Caris Life Sciences recently completed a $494 million IPO, marking a significant financial milestone amid a general freeze on biopharma initial public offerings. The company applies artificial intelligence and machine learning to analyze patient cancer samples, offering companion diagnostic capabilities that guide targeted cancer therapies. This commercial-stage precision medicine firm stands out as an exception in the industry by successfully accessing public markets to support its oncology-focused diagnostic platform.